中国生物制药(01177.HK):Well supported by nume...

发布于: 新闻转发:0回复:0喜欢:0
机构:招商证券 评级:BUY Company made satisfactory delivery in 4Q2017   Company reported 9%/33% growth in 2017 revenue and shareholder’s attributable net profit, all in RMB terms. The net profit was 6% behind consensus but in line... 网页链接